Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valda Murphy

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2005
Mixed effects versus fixed effects modelling of binary data with inter-subject variabilityValda Murphy, Adrian Dunne
Arthritis and Rheumatism|June 10, 2010
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging studyAlexander So, Marc De Meulemeester, Andrey Pikhlak, et al.
Arthritis Research & Therapy|March 29, 2011
Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging studyNaomi Schlesinger, Marc De Meulemeester, Andrey Pikhlak, et al.
Annals of the Rheumatic Diseases|May 16, 2012
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensionsNaomi Schlesinger, Rieke E Alten, Thomas Bardin, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2005
Mixed effects versus fixed effects modelling of binary data with inter-subject variabilityValda Murphy, Adrian Dunne
Arthritis and Rheumatism|June 10, 2010
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging studyAlexander So, Marc De Meulemeester, Andrey Pikhlak, et al.
Arthritis Research & Therapy|March 29, 2011
Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging studyNaomi Schlesinger, Marc De Meulemeester, Andrey Pikhlak, et al.
Annals of the Rheumatic Diseases|May 16, 2012
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensionsNaomi Schlesinger, Rieke E Alten, Thomas Bardin, et al.
Pageof 1